Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 594 JPY -0.07% Market Closed
Market Cap: 4.6T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Otsuka Holdings Co Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Otsuka Holdings Co Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Otsuka Holdings Co Ltd
TSE:4578
Change in Working Capital
-ÂĄ128.2B
CAGR 3-Years
-77%
CAGR 5-Years
-80%
CAGR 10-Years
-1%
Takeda Pharmaceutical Co Ltd
TSE:4502
Change in Working Capital
-ÂĄ346.6B
CAGR 3-Years
N/A
CAGR 5-Years
-28%
CAGR 10-Years
-15%
Daiichi Sankyo Co Ltd
TSE:4568
Change in Working Capital
ÂĄ217.2B
CAGR 3-Years
N/A
CAGR 5-Years
62%
CAGR 10-Years
26%
S
Shionogi & Co Ltd
TSE:4507
Change in Working Capital
ÂĄ35.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Change in Working Capital
-ÂĄ48.6B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Astellas Pharma Inc
TSE:4503
Change in Working Capital
-ÂĄ129.6B
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
-11%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.6T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co. Ltd. began its journey in 1921 as a small chemicals company in Naruto, Japan. Its evolution from those humble beginnings to a global pharmaceutical giant is marked by its relentless commitment to innovation and expansion. Today, Otsuka operates as a holding company, orchestrating a diversified portfolio across pharmaceuticals, nutraceuticals, consumer products, and medical devices. It has cultivated a unique philosophy: a balance between large-scale operations and niche markets. The company’s pharmaceutical sector, its most significant revenue contributor, is driven largely by advancements in CNS (central nervous system) treatments and nephrology. The success of its flagship product, Abilify, a leading antipsychotic, underscores Otsuka’s ability to combine market demands with cutting-edge research to sustain growth and profitability. In parallel, Otsuka nurtures its nutraceuticals wing, embodied by its signature Pocari Sweat and SoyJoy brands. These products epitomize the company’s strategy of creating and expanding niche markets, offering health-oriented products that resonate with evolving consumer health trends. This diversification into consumer products and nutraceuticals not only complements its pharmaceutical endeavors but also mitigates risks by tapping into varied revenue streams. By focusing on health and wellness broadly, Otsuka Holdings strategically positions itself to navigate the complexities of the global healthcare market, ensuring a resilient business model. Through this multifaceted approach, Otsuka sustains its growth, reaffirming its legacy as a dynamic and globally influential company.

Intrinsic Value
9 450.44 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Otsuka Holdings Co Ltd's Change in Working Capital?
Change in Working Capital
-128.2B JPY

Based on the financial report for Sep 30, 2024, Otsuka Holdings Co Ltd's Change in Working Capital amounts to -128.2B JPY.

What is Otsuka Holdings Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-1%

Over the last year, the Change in Working Capital growth was 17%. The average annual Change in Working Capital growth rates for Otsuka Holdings Co Ltd have been -77% over the past three years , -80% over the past five years , and -1% over the past ten years .

Back to Top